1Kim JH,Jeong MH,Rhew JY,et al.Long-term clinical outcomes of platelet glycoproteinⅡb/Ⅲa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome[J].Circ J,2005:69.
2Boersma E,Harrington RA,Moliternod J,et al.Platelet glycoproteinⅡb/Ⅲa inhibitors in acute coronary syndromes:a meta analysis of all major randomised clinical trials[J].Lancet,2002;359:189.
2STONE G W, MOLITERNO D J, BERTRAND M,et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein Ⅱb/Ⅲa in hibitors inpatients undergoing coronary stenting the TARGET trial[J]. Circulation, 2002,105 ：2345- 2354.
3CROUCH M A, NAPPI J M, CHEANG K I. Glycoprotein Ⅱb/Ⅲa receptor inbibitors in percutan coronary intervention and acute coronary syndrome [J].Ann Pharmacother, 2003, 37: 860-875.
4FUSTER V, BADIMON L, BADIMON J J, et al.The pathogenesis of coronary artery disease and the acute coronary syndromes [J]. N Engl J Med, 1992,326: 242- 250.
5The Restore Investigators. Effects of platelet Glycoprotein Ⅱb/Ⅲa Blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J]. Circulation ,1997, 96: 1445-1453.
6The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein Ⅱb/Ⅲ a receptor with tirofiban in unstable angina and non-Q-wave rnyocardial infarction[J]. N Engl J Med, 1998, 338:1488-1497.
7BOERSMA E, HARRINGTON R A, MOLITERNO D J, et al. Platelet glycoprotein Ⅱb/Ⅲa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials[J]. Lancet, 2002, 359:189-198.
8TCHENG J E, ELLIS S G, GEORGE B S, et al.Pharmacodynamics of chimetic glycoprotein Ⅱb/Ⅲa integrin antiplatelet antibody Fab TEs in high-risk coronary angioplasty[J]. Circulation, 1994, 90:1757-1764.
9Silber S, Albertsson P, Aviles FF, et al. Guildlines for percutaneous coronary interventions : The task force for percutaneous coronary interventions of the European society of cardiology [ J]. Eur Heart J, 2005, 26 : 804 - 847.
3Amsalem Y, Garty M, Chwartz R, et al. Prevalence and significance of unrecognized renal insufficiency in patients with heart failure[J]. Eur Heart J,2008 ;29(8) :1029-36.
4Kim JH, Jeong MH, Rhew JY, et al. Longterm clinical outcomes of platelet glycoprotein inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome[J]. Circ J,2005 ;69 (2) :159-64.
5KimJH,Jeong MH,Rhew JY, et al.Long-term clinical outcomes of plateletglycoprotein II b / Ilia inhibitor combined with low molecular feight heparin inpatients with acute coronary syndrome [J]. Circ J,2005:69.
6BoersmaE, Harrington RA, Molitemod J, et al. Platelet glycoprotein II b / IIIa inhibitors in acute coronary syndrome:a meta analysis of all major ran-domised clinical triaIs[J]. Lancet, 2002; 359: 189.
